{
    "clinical_study": {
        "@rank": "55390", 
        "brief_summary": {
            "textblock": "The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and\n      monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors,\n      medullary thyroid cancer and other cancers expressing somatostatin receptors."
        }, 
        "brief_title": "68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors", 
        "completion_date": {
            "#text": "November 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Carcinoid Tumors", 
            "Islet Cell (Pancreatic NET)", 
            "Other Neuroendocrine Tumors"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoid Tumor", 
                "Neuroendocrine Tumors"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Greater than 18 years-old at the time of radiotracer administration\n\n          -  Provides written informed consent\n\n          -  Known diagnosis of NET or suspected SSTR positive tumors by 111In-Octreotide scan,\n             18FDG-PET, or MRI of the abdomen when clinically indicated\n\n          -  Karnofsky score greater than 50 or ECOG Performance Status 0-2\n\n          -  Women of childbearing age must have a negative pregnancy test at screening/baseline\n\n          -  Able to remain still for duration of each imaging procedure (about one hour)\n\n        Exclusion Criteria:\n\n          -  Less than 18 years-old at the time of radiotracer administration\n\n          -  Pregnant or nursing\n\n          -  Serum creatinine >3.0 mg/dL\n\n          -  Hepatic enzyme levels more than 5 times upper limit of normal.\n\n          -  Use of any other investigational product or device within 30 days prior to dosing, or\n             known requirement for any other investigational agent prior to completion of all\n             scheduled study assessments.\n\n          -  Inability to lie still for the entire imaging time\n\n          -  Inability to complete the needed investigational and standard-of-care imaging\n             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)\n\n          -  Any additional medical condition, serious intercurrent illness, or other extenuating\n             circumstance that, in the opinion of the Investigator, may significantly interfere\n             with study compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "id_info": {
            "nct_id": "NCT01980732", 
            "org_study_id": "NET0017", 
            "secondary_id": "26988"
        }, 
        "intervention": {
            "arm_group_label": "68Ga-DOTA TATE PET/CT", 
            "description": "Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.", 
            "intervention_name": "68Ga-DOTA TATE", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Somatostatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 8, 2013", 
        "location": {
            "contact": {
                "email": "euodia@stanford.edu", 
                "last_name": "Euodia Jonathan", 
                "phone": "650-723-7419"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Andrei Iagaru", 
                "role": "Principal Investigator"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors", 
        "overall_contact": {
            "email": "euodia@stanford.edu", 
            "last_name": "Euodia Jonathan", 
            "phone": "6507234719"
        }, 
        "overall_contact_backup": {
            "email": "aholzer@stanford.edu", 
            "last_name": "Alison Holzer", 
            "phone": "6507254712"
        }, 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Andrei Iagaru", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Available", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980732"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Andrei Iagaru", 
            "investigator_title": "Assistant Professor of Radiology - Nuclear Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Andrei Iagaru", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "November 2013"
    }
}